<DOC>
	<DOC>NCT02927717</DOC>
	<brief_summary>Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma. Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.</brief_summary>
	<brief_title>An Italian Experience on Grade 3b Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<criteria>Diagnosis of grade 3b Follicular Lymphoma Age &gt; 18 years Frontline treatment with Rituximab containing chemotherapy Availability of histological sample for central review Other lymphoma diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Grade 3b Follicular Lymphoma</keyword>
	<keyword>2016 WHO Criteria</keyword>
	<keyword>Front-line treatment</keyword>
	<keyword>Rituximab</keyword>
</DOC>